Algenomics Secures Core Delivery Technology for "In Vivo CAR-T"
Combination of Circular RNA and Polymeric Carrier
Direct Reprogramming of Immune Cells via Intravenous Injection
Targeted Delivery to T Cells in the Spleen Confirmed
Potential for Next-Generation, Cost-Effective CAR-T Therapy
Algenomics announced on March 30 that it has developed an "in vivo CAR-T" therapeutic platform, which directly engineers immune cells inside the body, through joint research with a team from Inha University. The research findings were published in the international journal 'ACS Biomaterials Science & Engineering' on March 27.
Schematic overview of circular RNA delivery to T cells using spleen-specific polymeric carriers. Algenomics
View original imageThis study implemented a technology that delivers genes to immune cells via intravenous injection by combining circular RNA with a polyamino acid-based polymeric carrier. The research team confirmed that the intravenously administered RNA was mainly delivered to the spleen, which is rich in immune cells, and, in particular, was effectively delivered to T cells.
Conventional CAR-T therapy requires a complex process where a patient's cells are manipulated outside the body. In contrast, this technology delivers the CAR gene directly in vivo, suggesting the possibility of simplifying the process and reducing costs.
The research team explained that circular RNA demonstrated superior structural stability and sustained expression compared to conventional linear RNA. The polymeric carrier was also found to enhance intracellular delivery efficiency.
Hyunjin Kim, professor at Inha University who participated in the study, said, "Based on this technology, we will continue our research to develop polyamino acid polymer-based gene therapeutics."
Hot Picks Today
As Samsung Falters, Chinese DRAM Surges: CXMT Returns to Profit in Just One Year
- "Most Americans Didn't Want This"... Americans Lose 60 Trillion Won to Soaring Fuel Costs
- Tragedy Strikes on Part-time Job Commute... Man in His 30s Arrested for Drunk Driving Death of Freshman College Student
- "Striking Will Lead to Regret": Hyundai-Kia Employees Speak Out... Uneasy Stares Toward Samsung Union
- "Why Make Things Like This?" Foreign Media Highlights Bizarre Phenomenon Spreading in Korea
Seonguk Lee, CEO of Algenomics, stated, "We have confirmed that circular RNA technology can be applied to immune cell-targeted gene therapy," adding, "We will expand the development of immune cell-based therapeutics, including in vivo CAR-T."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.